42 Recruiting Melanoma Phase 2 Clinical Trials
Active phase 2 studies for melanoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Melanoma studiesPhase 2 Studies for Melanoma
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
📍 University of Arizona — Tucson, Arizona
View Study & Checklist ➔Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
📍 Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California
View Study & Checklist ➔Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
📍 University of Louisville — Louisville, Kentucky
View Study & Checklist ➔A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
📍 The Angeles Clinic — Los Angeles, California
View Study & Checklist ➔A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
📍 The Angeles Clinic and Research Institute - California — Los Angeles, California
View Study & Checklist ➔A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
📍 Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔Treating Patients With Melanoma and ALK Alterations With Ensartinib
📍 Memorial Sloan Kettering Monmouth — Middletown, New Jersey
View Study & Checklist ➔Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
📍 The Angeles Clinic and Research Institute — Los Angeles, California
View Study & Checklist ➔Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
📍 The University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
📍 Duke Cancer Center — Durham, North Carolina
View Study & Checklist ➔A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
📍 Hartford Healthcare Alliance (Data Collection Only) — Hartford, Connecticut
View Study & Checklist ➔A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
📍 UC San Diego — La Jolla, California
View Study & Checklist ➔A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
📍 Local Institution - 0007 — Anchorage, Alaska
View Study & Checklist ➔A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
📍 GSK Investigational Site — Los Angeles, California
View Study & Checklist ➔Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
📍 Rhode Island Hospital and The Miriam Hospital — Providence, Rhode Island
View Study & Checklist ➔Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
📍 Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
View Study & Checklist ➔Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
📍 University of South Alabama — Mobile, Alabama
View Study & Checklist ➔Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Axitinib + Ipilimumab in Advanced Melanoma
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
📍 Local Institution - 0010 — Tucson, Arizona
View Study & Checklist ➔A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
📍 Research Site — Los Angeles, California
View Study & Checklist ➔PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
📍 M.D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
📍 Call for Information (Investigational Site 0019) — Aurora, Colorado
View Study & Checklist ➔LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
📍 BCCA - Abbotsford — Abbotsford British Columbia, British Columbia
View Study & Checklist ➔Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
📍 Huntsman Cancer Institute — Salt Lake City, Utah
View Study & Checklist ➔Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of IBI363 in Subjects with Advanced Solid Malignancies
📍 University of California, San Francisco (UCSF) — San Francisco, California
View Study & Checklist ➔A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
📍 James Graham Brown Cancer Center-University of Louisville — Louisville, Kentucky
View Study & Checklist ➔Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
📍 Yale — New Haven, Connecticut
View Study & Checklist ➔Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
📍 Baptist - MD Anderson Cancer Center — Jacksonville, Florida
View Study & Checklist ➔A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
📍 Research Site — Grand Rapids, Michigan
View Study & Checklist ➔A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
📍 Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
View Study & Checklist ➔Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
📍 Chao Family Comprehensive Cancer Center University of California, Irvine — Orange, California
View Study & Checklist ➔Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
📍 The Angeles Clinic at Cedars Sinai — Los Angeles, California
View Study & Checklist ➔